IP Library Granted Patent US 10,864,159
Granted Patent B2
US 10,864,159 · App. 16/010,739 · Granted Dec 15, 2020

Method and composition for treating ocular hypertension and glaucoma

Inventors: Timo Reunamaki (Tampere, FI); Pertti Pellinen (Lempaala, FI); Olli Oksala (Tampere, FI); Kari Lehmussaari (Tampere, FI)
Assignees: SANTEN PHARMACEUTICAL CO., LTD.; AGC INC.
A61K9/0048A61K9/08A61K31/5575A61K47/10A61K47/183A61K47/26A61P27/06A61K47/02Y02A50/30Y10S514/913
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,864,159
App. No.
16/010,739
Granted
Dec 15, 2020
Kind
B2
Abstract

The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition.

Claims (5)

1. A method for treating ocular hypertension and glaucoma to a subject in need thereof, by administrating an ophthalmic aqueous solution consisting of 0.0015% w/v tafluprost as an active ingredient, 0.075% w/v polysorbate 80, 0.05% w/v disodium edetate, 2.25% w/v glycerol, 0.2% w/v sodium dihydrogen phosphate dihydrate, one or more pH adjusters, and water.

2. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 1 , wherein the ophthalmic aqueous solution is packaged in a single dose or unit dose container.

3. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 1 , wherein the ophthalmic aqueous solution is packaged in a container made of a low density polyethylene.

4. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 2 , wherein the container is made of a low density polyethylene.

5. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 4 , wherein the container contains no more than 10% of any material other than polyethylene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2018
From: REUNAMAKI, TIMO; PELLINEN, PERTTI; OKSALA, OLLI; LEHMUSSAARI, KARI
To: SANTEN PHARMACEUTICAL CO., LTD.; ASAHI GLASS COMPANY, LIMITED
Reel/Frame 047159/0513 →
CHANGE OF NAME Recorded Sep 7, 2018
From: ASAHI GLASS COMPANY, LIMITED
To: AGC INC.
Reel/Frame 047278/0081 →
Priority Claims (1)
EP 08397513 · May 30, 2008 · regional
Continuity (2)
Division 12995351
Related Publication 20180289618A1 · Oct 11, 2018